Table 1 Patient demographic & operative data
UF n = 109 | OPCAB n = 111 | p - Value | |
|---|---|---|---|
Age (year, mean ± SD) | 64.23 ± 8.85 | 66.62 ± 9.41 | 0.054 |
Male, n (%) | 83 (76.15) | 70 (63.06) | 0.041 |
NYHA functional class, n (%) | 0.075 | ||
Class I | 9 (8.26) | 18 (16.22) | |
Class II | 73 (66.97) | 57 (51.35) | |
Class III | 24 (22.02) | 29 (26.13) | |
Class IV | 3 (2.75) | 7 (6.31) | |
CCS class, n (%) | < 0.001 | ||
Class 0 | 21 (19.27) | 8 (7.21) | |
Class I | 48 (44.04) | 33 (29.73) | |
Class II | 30 (27.52) | 40 (36.04) | |
Class III | 7 (6.42) | 21 (18.92) | |
Class IV | 3 (2.75) | 9 (8.11) | |
Body weight (kg, mean ± SD) | 59.8 ± 10.32 | 60.0 ± 13.37 | 0.918 |
Body height (cm, mean ± SD) | 159.9 ± 7.89 | 156.4 ± 17.49 | 0.059 |
EuroSCORE II (%, mean ± SD) | 4.86 ± 3.82 | 3.72 ± 4.67 | 0.048 |
Pre-op creatinine (mg/dL, Mean ± SD) | 4.22 ± 3.02 | 2.25 ± 2.14 | < 0.001 |
Pre-op eGFR (ml/min, Mean ± SD) | 22.70 ± 16.44 | 40.59 ± 15.72 | < 0.001 |
Ejection fraction (%, Mean ± SD) | 48.1 ± 15.55 | 53.0 ± 13.4 | 0.012 |
Previous medication, n (%) | |||
Betablocker | 76 (69.72) | 64 (57.66) | 0.070 |
ACEI/ARBs | 28 (25.69) | 64 (57.66) | < 0.001 |
Calcium channel blocker | 42 (38.53) | 40 (36.04) | 0.781 |
Nitrate | 61 (55.96) | 84 (75.68) | < 0.001 |
Statin | 94 (86.24) | 101 (90.99) | 0.294 |
Underlying disease, n (%) | |||
Diabetes mellitus with no Insulin therapy | 25 (22.93) | 35 (31.53) | 0.521 |
Insulin injection therapy | 28 (25.68) | 29 (26.13) | 0.532 |
Hypertension | 105 (96.33) | 102 (91.89) | 0.252 |
Dyslipidemia | 95 (87.15) | 83 (74.77) | 0.025 |
Old cerebrovascular disease | 6 (5.5) | 9 (8.11) | 0.594 |
History of myocardial ischemia | 23 (21.1) | 17 (15.32) | 0.297 |
COPD | 1 (0.9) | 2 (1.8) | 0.507 |
Chronic kidney disease, n (%) | < 0.001 | ||
Stage III (IIIa & IIIb) | 34 (31.19) | 83 (74.77) | |
Stage IV | 25 (22.93) | 15 (13.51) | |
End stage renal disease | 49 (44.95) | 13 (11.71) | |
Coronary artery disease, n (%) | 0.066 | ||
Single vessel | 5 (4.58) | 1 (0.9) | |
Double vessel | 19 (17.43) | 11 (9.91) | |
Triple vessel | 85 (79.43) | 99 (89.19) | |
Left main disease, n (%) | 36 (33.02) | 40 (36.04) | 0.372 |
Pre-op IABP, n (%) | 4 (4.6) | 17 (15.32) | 0.005 |
Operated surgeon, n (%) | < 0.001 | ||
1 | 9 (8.26) | 73 (65.77) | |
2 | 53 (48.62) | 6 (5.41) | |
3 | 16 (14.68) | 26 (23.42) | |
4 | 2 (1.83) | 1 (0.9) | |
5 | 13 (11.93) | 5 (4.5) | |
6 | 16 (14.68) | 0 (0) | |
Status of surgery, n (%) | 0.939 | ||
Elective | 98 (89.90) | 98 (88.29) | |
Urgent | 8 (7.33) | 10 (9.01) | |
Emergency | 3 (2.75) | 3 (2.7) | |
Preoperative MAP (mmHg, Mean ± SD) | 84.54 ± 12.97 | 89.91 ± 12.49 | 0.002 |
Number of anastomosis (Mean ± SD) | 4.15 ± 1.21 | 4.06 ± 1.14 | 0.559 |
Use of radial arterial graft, n (%) | 47 (43.11) | 56 (50.45) | 0.284 |
Operative time (minutes, Mean ± SD) | 298.56 ± 85.86 | 260.52 ± 83.4 | 0.001 |
Total hemofiltration time (min, Mean ± SD) | 9.62 ± 0.95 | - | - |
Ultrafiltration volume (ml, Mean ± SD) | 1328.35 ± 776.97 | - | - |
Peri-mediastinal drainage in first 24 h. (ml, Mean ± SD) | 402.67 ± 300.5 | 475.4 ± 211.6 | 0.295 |
Blood transfusion, n (%) | 45 (41.28) | 46 (41.4) | 0.780 |
Number of post-op PRC usage (unit, mean ± SD) | 1.60 ± 1.04 | 1.39 ± 0.6 | 0.512 |
Early re-operation, n (%) | 6 (5.55) | 1 (0.9) | 0.064 |
Post-op inotropic drug | |||
Norepinephrine | 49 (44.95) | 38 (34.2) | 0.068 |
Adrenaline | 23 (21.1) | 6 (5.41) | < 0.001 |
Dobutamine | 13 (11.92) | 10 (9.0) | 0.516 |
Milrinone | 21 (19.26) | 4 (3.6) | < 0.001 |
Propensity scores (mean ± SD) | 0.75 ± 0.25 | 0.25 ± 0.25 | < 0.001 |